Skip to main content

Advertisement

SpringerLink
Log in

Preempting and preventing drug-induced liver injury

  • News & Views
  • Published:

From Nature Genetics

View current issue Submit your manuscript

A new study reports that susceptibility to drug-induced liver injury by the cyclooxygenase 2 (COX-2) inhibitor lumiracoxib is associated with a human lymphocyte antigen (HLA) class II haplotype. This finding suggests that those at risk of hepatotoxicity can be identified by HLA genotyping, raising the possibility that lumiracoxib can be resurrected as a useful drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Aithal, G.P. & Day, C.P. et al. Clin. Liver. Dis. 11, 563–575, vi–vii (2007).

    Article  Google Scholar 

  2. Goldkind, L. & Laine, L. et al. Pharmacoepidemiol. Drug Saf. 15, 213–220 (2006).

    Article  CAS  Google Scholar 

  3. Traversa, G. et al. Br. Med. J. 327, 18–22 (2003).

    Article  CAS  Google Scholar 

  4. Singer, J.B. et al. Nat. Genet. 42, 711–714 (2010).

    Article  CAS  Google Scholar 

  5. Kindmark, A. et al. Pharmacogenomics J. 8, 186–195 (2008).

    Article  CAS  Google Scholar 

  6. Daly, A.K. et al. Nat. Genet. 41, 816–819 (2009).

    Article  CAS  Google Scholar 

  7. Hautekeete, M.L. et al. Gastroenterology 117, 1181–1186 (1999).

    Article  CAS  Google Scholar 

  8. Donaldson, P.T. et al. J. Hepatol. (in the press) (2010).

  9. Donaldson, P.T. et al. Gut 53, 599–608 (2004).

    Article  CAS  Google Scholar 

  10. Schnitzer, T.J. et al. Lancet 364, 665–674 (2004).

    Article  CAS  Google Scholar 

  11. Farkouh, M.E. et al. Lancet 364, 675–684 (2004).

    Article  CAS  Google Scholar 

  12. Rubenstein, J.H. & Laine, L. et al. Aliment. Pharmacol. Ther. 20, 373–380 (2004).

    Article  CAS  Google Scholar 

  13. de Abajo, F.J., Montero, D., Madurga, M. & Garcia Rodriguez, L.A. Br. J. Clin. Pharmacol. 58, 71–80 (2004).

    Article  Google Scholar 

  14. Mallal, S. et al. N. Engl. J. Med. 358, 568–579 (2008).

    Article  Google Scholar 

  15. Hirata, K. et al. Pharmacogenomics J. 8, 29–33 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Guruprasad P. Aithal is at the Nottingham Digestive Diseases Centre, National Institute for Health Research Biomedical Research Unit, Nottingham University Hospital National Health Service Trust, Nottingham, UK.,

    Guruprasad P Aithal

  2. Ann K. Daly is at the Institute of Cellular Medicine, Newcastle University Medical School, Framlington Place, Newcastle upon Tyne, UK.,

    Ann K Daly

Authors
  1. Guruprasad P Aithal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ann K Daly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ann K Daly.

Ethics declarations

Competing interests

A.K.D. received funding from AstraZeneca and the International Serious Adverse Events Consortium. A.K.D. also consulted with Johnson and Johnson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aithal, G., Daly, A. Preempting and preventing drug-induced liver injury. Nat Genet 42, 650–651 (2010). https://doi.org/10.1038/ng0810-650

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng0810-650

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation